Provectus has announced that a second group of subjects has been treated in the company's Phase I clinical trial of PV-10 (Provecta) for ablation of metastatic melanoma, an aggressive and often fatal form of skin cancer. Treatment with PV-10 was well tolerated by all subjects, with no evidence of systemic or serious local side effects.

The study consists of 20 subjects, and is being conducted at the Sydney Melanoma Unit and the Newcastle Melanoma Unit, both located in New South Wales, Australia. Each subject enrolled in the study has one or more tumors treated with a single injection of PV-10 and the local response to the treatment is then observed for a period of 12 to 24 weeks.